Search

Publications

Ruxolitinib for the management of myelofibrosis: Results of an international physician survey. Ellis MH, Koren-Michowitz M, Lavi N, Vannucchi AM, Mesa R, Harrison CN. Leuk Res. 2017 Oct;61:6-9. doi: 10. 1016/j. leukres. 2017. 08. 002.

EHA launches Global Hematology Professionals’ Survey – make your voice heard

Mar 27 2023 Posted in Press releases

The Hague (Netherlands), March 27, 2023.

EHA Pediatric Hemato-Oncology Course programme

April 10, 202414:00–17:30: Red Cell and ConsultativeWelcome and presentation of the course. Aims, expectations, and a brief look back. Presenters and topics
M. de Montalembert: Difficult management problems in sickle cell disease
M. D.

SWG Educational Activities

SWG meeting, EHA2023 CongressGuidelines SessionSession title‘The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children.

Meeting program

Saturday, November 4*All times are in EET.

EHA Pediatric Hemato-Oncology Course 2024

Join us in Sorrento to develop your problem-solving skills and exchange ideas in a friendly and supportive environment. DatesApril 10–13, 2024. LocationGrand Hotel Riviera, Sorrento, Italy.

Highlights of Past EHA (HOPE) Latin America (LA) 2023 - report

Nov 28 2023 Posted in Meeting reports

October 26, 2023 – São Paulo, Brazil

Meeting chairs:

A Almeida - President EHA

JF Comenalli Marques Jr - President ABHH

C Chiattone - President HEMO 2023

This year, the HOPE LA meeting was held in collaboration with the Associação Brasileira de Hematologia Hemoterapia e…

Renew your membership

If you want to keep enjoying the benefits of EHA membership— from around-the-clock access to EHA Campus to discounts on EHA Congress registration—you'll need to renew your membership.

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

Jun 14 2013

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.